Amneal Pharmaceuticals, Inc.
AMRXNasdaq
$17.85
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↑ +116.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.9B
Enterprise Value
$8.2B
P/E
48.2
P/S
1.9
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
4.1%
Dividend Yield
—
Revenue (TTM)
$3.0B
Net Income (TTM)
$122.1M
Free Cash Flow (TTM)
$240.8M
Gross Margin
38.7%
Operating Margin
14.3%
Net Margin
4.0%
ROE
-268.9%
ROIC
18.6%
Debt / Equity
-56.6
Net Cash
-$2.4B
Return 1Y
+116.6%
Company profile
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products. The company operates through three segments: Generics, Specialty, and AvKARE. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
- CEO
- Chintu Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7,600
- Headquarters
- New Jersey
- Website
- amneal.com
Management & directors
- Boyer Andrew SExecutive Vice President
- Daly Jason B.EVP, Chief Legal Officer
- Konidaris TasosExecutive Vice President & CFO
- Patel ChintuCo-CEO
- Patel Chirag K.President & Co-CEO
- Shah NikitaExecutive Vice President
Roles derived from SEC Form 4 filings.
Earnings
AMRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$722.5M↑ +3.9%
Diluted EPS$0.19↑ +375.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| Gross profit | $628.4M | $769.0M | $784.7M | $820.6M | $1.0B | $1.1B |
| Operating income | $91.2M | $152.7M | -$94.9M | $204.4M | $249.3M | $394.1M |
| Net income | $67.8M | $13.2M | -$270.6M | -$84.0M | -$116.9M | $72.1M |
| Diluted EPS | $0.61 | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 |
| Operating cash flow | $379.0M | $241.8M | $65.1M | $345.6M | $295.1M | $340.0M |
| Free cash flow | $322.6M | $194.1M | $18.7M | $302.4M | $243.2M | $269.9M |
| Gross margin | 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% |
| Operating margin | 4.6% | 7.3% | -4.3% | 8.5% | 8.9% | 13.1% |
| Net margin | 3.4% | 0.6% | -12.2% | -3.5% | -4.2% | 2.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $701.8M | $702.5M | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M |
| Gross profit | $249.9M | $269.6M | $262.9M | $255.9M | $286.3M | $274.0M | $297.2M | $320.1M |
| Operating income | $95.5M | $88.8M | $75.8M | $100.3M | $111.4M | $70.3M | $112.0M | $141.8M |
| Net income | $6.0M | -$156,000.00 | -$31.1M | $12.2M | $22.4M | $2.4M | $35.1M | $62.3M |
| Diluted EPS | $0.02 | $0.00 | -$0.10 | $0.04 | $0.07 | $0.01 | $0.10 | $0.19 |
| Operating cash flow | $39.7M | $141.8M | $118.1M | $7.4M | $83.8M | $118.5M | $130.3M | -$26.7M |
| Free cash flow | $29.0M | $124.8M | $102.9M | -$5.8M | $61.0M | $106.2M | $108.5M | -$34.9M |
| Gross margin | 35.6% | 38.4% | 36.0% | 36.8% | 39.5% | 34.9% | 36.5% | 44.3% |
| Operating margin | 13.6% | 12.6% | 10.4% | 14.4% | 15.4% | 9.0% | 13.8% | 19.6% |
| Net margin | 0.9% | -0.0% | -4.3% | 1.8% | 3.1% | 0.3% | 4.3% | 8.6% |
Company news
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-11 | Autor Deborah M. | Sale | 34,819 | $12.94 | $450,557.86 | filing |
| 2026-05-07 | George Jeffrey P. | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | Nark Ted C | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | Patel Gautam | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | Kiely John | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | MEISTER PAUL M | Option exercise | 48,747 | — | — | filing |
| 2026-05-07 | Autor Deborah M. | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | Yanai Shlomo | Option exercise | 34,819 | — | — | filing |
| 2026-05-07 | BUCHI J KEVIN | Option exercise | 34,819 | — | — | filing |
| 2026-03-04 | Patel Chirag K.· President & Co-CEO | Tax withholding | 37,825 | $13.30 | $503,072.50 | filing |
| 2026-03-04 | Patel Chintu· Co-CEO | Tax withholding | 28,983 | $13.30 | $385,473.90 | filing |
| 2026-03-04 | Konidaris Tasos· Executive Vice President & CFO | Tax withholding | 22,035 | $13.30 | $293,065.50 | filing |
| 2026-03-04 | BOYER ANDREW S· Executive Vice President | Tax withholding | 19,136 | $13.30 | $254,508.80 | filing |
| 2026-03-04 | Shah Nikita· Executive Vice President | Tax withholding | 17,976 | $13.30 | $239,080.80 | filing |
| 2026-03-04 | Daly Jason B.· EVP, Chief Legal Officer | Tax withholding | 15,580 | $13.30 | $207,214.00 | filing |
| 2026-03-04 | Daly Jason B.· EVP, Chief Legal Officer | Option exercise | 35,880 | — | — | filing |
| 2026-03-04 | Patel Chirag K.· President & Co-CEO | Option exercise | 92,593 | — | — | filing |
| 2026-03-04 | Shah Nikita· Executive Vice President | Option exercise | 35,880 | — | — | filing |
| 2026-03-04 | Konidaris Tasos· Executive Vice President & CFO | Option exercise | 43,982 | — | — | filing |
| 2026-03-04 | Patel Chintu· Co-CEO | Option exercise | 92,593 | — | — | filing |
| 2026-03-04 | BOYER ANDREW S· Executive Vice President | Option exercise | 38,195 | — | — | filing |
| 2026-03-03 | Patel Chintu· Co-CEO | Tax withholding | 315,885 | $13.31 | $4.2M | filing |
| 2026-03-03 | Patel Chirag K.· President & Co-CEO | Tax withholding | 297,537 | $13.31 | $4.0M | filing |
| 2026-03-03 | Konidaris Tasos· Executive Vice President & CFO | Tax withholding | 229,817 | $13.31 | $3.1M | filing |
| 2026-03-03 | BOYER ANDREW S· Executive Vice President | Tax withholding | 199,175 | $13.31 | $2.7M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.